Company news
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) news
Every Rigel Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
August 13, 2026
Rigel Reports Second Quarter 2026 Financial Results
August 4, 2026
Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant)
July 29, 2026
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
July 28, 2026
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
June 16, 2026
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
May 21, 2026
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m...
May 12, 2026
Rigel Reports First Quarter 2026 Financial Results
May 5, 2026
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
April 28, 2026
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Cl...
March 31, 2026
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 3, 2026
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
February 24, 2026
Rigel Appoints Michael P. Miller to the Board of Directors
February 3, 2026
Rigel Provides Business Update and 2026 Outlook
January 12, 2026
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
January 9, 2026
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meetin...
December 7, 2025
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
November 26, 2025
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology...
November 17, 2025
Rigel to Present at the Jefferies Global Healthcare Conference in London
November 12, 2025
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
November 4, 2025
Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
November 3, 2025
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
October 29, 2025
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
October 8, 2025
Rigel to Participate in Upcoming September Investor Conferences
August 26, 2025
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
August 5, 2025
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update
July 29, 2025
Rigel to Present at the Jefferies Global Healthcare Conference
May 28, 2025
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
May 22, 2025
Rigel Reports First Quarter 2025 Financial Results and Provides Business Update
May 6, 2025
Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update
April 29, 2025
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
March 27, 2025
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors
March 10, 2025
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 4, 2025
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update
February 25, 2025
Rigel Provides Business Update and 2025 Outlook
January 13, 2025
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
January 9, 2025
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
December 2, 2024
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
November 7, 2024
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
November 5, 2024
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
October 31, 2024
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
October 24, 2024
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 4, 2024
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
September 5, 2024
Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
September 3, 2024
Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
August 6, 2024
Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update
July 30, 2024
Rigel Announces Reverse Stock Split
June 25, 2024
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
June 24, 2024
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
June 14, 2024